Q-omics provides the consensus-scored KDM5A profile across patient tissues and cancer cell-line models. KDM5A expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, KDM5A is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, KDM5A RNA expression shows 20,619 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight SCLC, HNSC, and ACC as cancer lineages where KDM5A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KDM5A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KDM5A survival associations across molecular data types. KDM5A RNA expression shows survival associations in the most cancer types (23), followed by mutation status (6) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KDM5A RNA expression–survival associations across cancer types. High KDM5A expression shows unfavorable associations in ACC, MESO, LGG and KIRP, but favorable associations in SCLC and KIRC. The SCLC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SCLC as the clearest survival context for KDM5A RNA expression.
This table summarizes KDM5A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 3. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for KDM5A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KDM5A shows lower tumor expression in THCA and higher tumor expression in HNSC, STAD, LIHC, CHOL and LUSC. The HNSC box plot shows higher KDM5A RNA expression in tumor versus normal tissue (log2 FC = +0.796, t-test p < 0.001).
This table shows molecular features associated with KDM5A in patient tissues and cancer cell lines. In patient samples, KDM5A shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, KDM5A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BLOOD_Leukemia.
